Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 304 participants.

Also called NCT06723717

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 304 participants (planned count) (from the registry)
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild (from the registry)
Registry
  • NCT NCT06723717
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06723717. Randomized; single masking; primary purpose prevention. Start 2025-09-26 (actual); primary completion 2028-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months
Acronym
RESET
Condition
Ruptured Aneurysm of Intracranial Artery
Condition
SAH (Subarachnoid Hemorrhage)
Condition
Delayed Cerebral Ischemia
Intervention (Drug)
Daily infusion of dornase alfa
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild (class: research network)

Record details

Record id
cardio:ct-nct06723717
Content hash
923001255526b7e57d30e326eb97f22f080be315fa93b2ab6870fce425f5fcca